Based on the properties of protamine, Xu et al. developed an aptamer-protamine-siRNA nanoparticle (APR), which consists of protamine, ErbB3 aptamer, and siSurvivin, for targeting and recognizing ErbB3-positive breast cancer cells. This evidence concerns the gene ERBB3 and breast carcinoma.